SFI
DNTH icon

Susquehanna Fundamental Investments’s Dianthus Therapeutics DNTH Stock Holding History

Susquehanna Fundamental Investments’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,121
Closed -$488K – 1738
2021
Q2 		$488K Sell
3,121
-68
-2% -$12.5K 0.01% 1178
2021
Q1 		$604K Sell
3,189
-262
-8% -$44.1K 0.01% 1080
2020
Q4 		$433K Sell
3,451
-743
-18% -$84.2K 0.01% 1153
2020
Q3 		$456K Buy
+4,194
New +$497K 0.01% 909

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna Fundamental Investments's DNTH Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Dianthus Therapeutics (DNTH) in Q3 2021, closing a stake of 3,121 shares — an estimated $488K sold.

Susquehanna Fundamental Investments first reported a position in DNTH in Q3 2020 and held it in 4 quarters. The position peaked at $604K in Q1 2021. 93 funds tracked by Wall St. Rank hold DNTH as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Dianthus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 3,121 Dianthus Therapeutics shares in Q3 2021, an estimated $488K.
  • Susquehanna Fundamental Investments first reported a position in Dianthus Therapeutics in Q3 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Dianthus Therapeutics position peaked at $604K in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.